Mean age of patients, gender distribution, KRAS mutational status of patients as well as time from diagnosis of colorectal cancer was consistent between the German CUP and the phase 3 trial, though the mean body surface area in the CUP was slightly higher (1.87 vs. 1.781, respectively) leading to a higher daily dose of FTD/TPI (130 mg) compared with the RECOURSE trial (120 mg) (suppl. Here, KRAS is linked to colorectal cancer.